STATE-OF-THE-ART PAPER
Pulmonary Arterial Hypertension
Kelly M. Chin, MD*,* and
Lewis J. Rubin, MD
* Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California.
Manuscript received November 29, 2007;
revised manuscript received December 28, 2007,
accepted January 6, 2008.
* Reprint requests and correspondence: Dr. Kelly M. Chin, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Mail Code 75390-8550, Dallas, Texas 75235. (Email: Kelly.Chin{at}utsouthwestern.edu).
Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10 years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2 separate classes. Over this same period, the classification of pulmonary hypertension has been revised with changes including the substitution of the term idiopathic for primary PAH and an expanded list of conditions felt to be associated with the development of PAH. Long-term follow-up studies have provided better information on prognosis and expected outcomes with treatment, with particularly valuable data on reassessment of prognosis after treatment with epoprostenol. Combination therapy is more frequently being used, and limited data on novel therapies such as stem cell transplantation have been published. The purpose of this review is to describe the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH.
|
Abbreviations and Acronyms
| | BMPR = bone morphogenetic protein receptor | | CHF = congestive heart failure | | HIV = human immunodeficiency virus | | NO = nitric oxide | | PAH = pulmonary arterial hypertension | | RV = right ventricle/ventricular |
|
This article has been cited by other articles:
|
|
|
|
 
L. P. Badano, C. Ginghina, J. Easaw, D. Muraru, M. T. Grillo, P. Lancellotti, B. Pinamonti, G. Coghlan, M. P. Marra, B. A. Popescu, et al.
Right ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effects
Eur J Echocardiogr,
October 7, 2009;
(2009)
jep152v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Morecroft, L. Pang, M. Baranowska, M. Nilsen, L. Loughlin, Y. Dempsie, C. Millet, and M. R. MacLean
In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension
Cardiovasc Res,
September 25, 2009;
(2009)
cvp306v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Galie, L. Negro, and G. Simonneau
The use of combination therapy in pulmonary arterial hypertension: new developments
Eur. Respir. Rev.,
September 1, 2009;
18(113):
148 - 153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Burke, M. G. Frid, C. L. Kunrath, V. Karoor, A. Anwar, B. D. Wagner, D. Strassheim, and K. R. Stenmark
Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment
Am J Physiol Lung Cell Mol Physiol,
August 1, 2009;
297(2):
L238 - L250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.L. Handoko, F.S. de Man, C.M. Happe, I. Schalij, R.J.P. Musters, N. Westerhof, P.E. Postmus, W.J. Paulus, W.J. van der Laarse, and A. Vonk-Noordegraaf
Opposite Effects of Training in Rats With Stable and Progressive Pulmonary Hypertension
Circulation,
July 7, 2009;
120(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. T. B. Mouchaers, I. Schalij, A. M. G. Versteilen, A. M. Hadi, G. P. van Nieuw Amerongen, V. W. M. van Hinsbergh, P. E. Postmus, W. J. van der Laarse, and A. Vonk-Noordegraaf
Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension
Am J Physiol Heart Circ Physiol,
July 1, 2009;
297(1):
H200 - H207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Ferreira, V. Shenoy, Y. Yamazato, S. Sriramula, J. Francis, L. Yuan, R. K. Castellano, D. A. Ostrov, S. P. Oh, M. J. Katovich, et al.
Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
June 1, 2009;
179(11):
1048 - 1054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Humbert
Update in Pulmonary Hypertension 2008
Am. J. Respir. Crit. Care Med.,
April 15, 2009;
179(8):
650 - 656.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ben-Yehuda and C. Barnett
Magnetic resonance assessment of pulmonary artery compliance a promising diagnostic and prognostic tool in pulmonary hypertension?
J. Am. Coll. Cardiol. Img.,
March 1, 2009;
2(3):
296 - 298.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. McGoon and G. C. Kane
Pulmonary Hypertension: Diagnosis and Management
Mayo Clin. Proc.,
February 1, 2009;
84(2):
191 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Meads, S. P. McKenna, N. Doughty, C. Das, W. Gin-Sing, J. Langley, and J. Pepke-Zaba
The responsiveness and validity of the CAMPHOR Utility Index
Eur. Respir. J.,
December 1, 2008;
32(6):
1513 - 1519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Oudiz and L. J. Rubin
Exercise-Induced Pulmonary Arterial Hypertension: A New Addition to the Spectrum of Pulmonary Vascular Diseases
Circulation,
November 18, 2008;
118(21):
2120 - 2121.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Taichman
Therapy for Pulmonary Arterial Hypertension: The More, the Merrier?
Ann Intern Med,
October 21, 2008;
149(8):
583 - 585.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Schrier and S. Bansal
Pulmonary Hypertension, Right Ventricular Failure, and Kidney: Different from Left Ventricular Failure?
Clin. J. Am. Soc. Nephrol.,
September 1, 2008;
3(5):
1232 - 1237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Kapoor
Pulmonary Artery Hypertension: The Link Between Prostanoids and Bloodstream Infections
J. Am. Coll. Cardiol.,
August 26, 2008;
52(9):
792 - 792.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Chin and L. J. Rubin
Reply
J. Am. Coll. Cardiol.,
August 26, 2008;
52(9):
792 - 792.
[Full Text]
[PDF]
|
|
|
|
